Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference March 22, 2022 • 8:00 AM EDT
Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting March 15, 2022 • 7:00 AM EDT
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update February 11, 2022 • 8:15 AM EST
Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022 February 4, 2022 • 7:00 AM EST
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells February 3, 2022 • 7:00 AM EST
Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma January 12, 2022 • 8:00 AM EST
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference January 5, 2022 • 8:00 AM EST
Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021 December 7, 2021 • 8:00 AM EST
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma November 30, 2021 • 8:00 AM EST
Kintara Presents Updates on Two Phase 2 Clinical Studies at the 2021 Society for Neuro-oncology Annual Meeting November 18, 2021 • 8:00 AM EST